Eilean Therapeutics
eileanther.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Team
51-200
employees, estimated range
Backers
1
OrbiMed
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2022
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
OrbiMed Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
We navigate evolutionary data to translate extreme biological adaptations into first-in-class medicines. Learn more about our process.
Stelexis BioSciences is a clinical-stage biopharmaceutical company created to accelerate novel treatments that aim to eradicate…
Company Overview Rooted in two decades of discovery Santero Therapeutics is a Belgian biotechnology company developing first-in-class…
Innovating life-changing medicines for cancer patients. At Kumquat, we're on a mission to transform cancer treatment by delivering durable…
Brenig Therapeutics develops innovative small-molecule therapies for neurodegenerative diseases, including LRRK2 inhibitors targeting…
Overview
Targeting escape mutations in hematological cancers with first and best in class medicines.
News
Eilean Therapeutics Advances ZE74-0282, a Highly Selective Inhibitor of Mutated JAK2 V617F, into First-in-Human Clinical Development
Read more
Report
Eilean Therapeutics to Present First-in-Class, Wild-Type-Sparing JAK2-JH2/V617F Inhibitor ZE74-0282 at ASH 2025 and Initiate Clinical Studies in December 2025
Eilean Therapeutics LLC, a biotechnology company developing next-generation precision medicines for cancer and immune-inflammatory diseases, today announced the upcoming presentation of preclinical data for its first-in-class, wild-type-sparing JAK2-JH2/V
Read more
Report
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and Immunology
Eilean Therapeutics LLC, a biopharmaceutical company dedicated to developing best-in-class and first-in-class small-molecule therapies targeting genetic escape mutations in cancer and advancing innovative treatments for chronic inflammatory and immune dis
Read more
Report
Eilean Therapeutics Presents First-in-Class MALT1 Degrader TE205 Demonstrating In Vivo Efficacy in Ulcerative Colitis at the 4th International Conference on Microbiology and ...
Read more
Report